AURINIA PHARMACEUTICALS INC
AUPHNASDAQ🏆 #1809 by market capEarnings Feb 24 · PostUS Equity
$17.20▼ $0.17 (−0.98%)
Market closed · at closeTrack AUPH
Get earnings, price moves & breaking news on Telegram
24h▼ 1.0%
7d▲ 2.1%
14d▲ 4.1%
30d▲ 6.2%
ytd▲ 8.0%
1y▲ 41.9%
🏦Market Cap
$2.29B
Small Cap
📈Revenue Growth (YoY)
19.8%
Healthy
📊Gross Margin
90.4%
High
💵FCF Margin
56.2%
Strong
⚖️P/S Ratio
7.4x
Fair
Otter Score
76
Strong
Trading Snapshot
- Day Range
- $17.11 – $17.56
- 52-Week Range
- $11.96 – $19.25
- Volume (shares)
- 72,526
- Avg Volume (shares)
- —
- Shares Outstanding
- 133.1M
- Next Earnings
- 2027-02-24
Fundamentals Snapshot
- Annual Revenue
- $283M
- Last Q Revenue
- $83M
- P/E Ratio
- 7.3
- P/S Ratio
- 7.4x
- EPS (TTM)
- $2.29
- Dividend Yield
- —
- Dilution (1yr)
- −6.1%
AURINIA PHARMACEUTICALS INC
AUPHFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$283M▲ +20.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
88.5%▲ +0.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$105M▼ −2338.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$135M▲ +207.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
138.7M▼ −6.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$5M▲ +$1M YoY
StockOtter · stockotter.spaceAbout AURINIA PHARMACEUTICALS INC
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Strong
76/100
Analyst Ratings
ⓘConsensus
Buy
13 analysts
Strong Buy3
Buy7
Hold3
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.